Amgen's Tezspire Data Was Consistent. The Stock Is No Longer Cheap.

The newest piece of Amgen's (AMGN) severe-asthma story is a real-world study built around the patients who usually get left out of drug trials. The PASSAGE study followed 286 adults and adolescents with severe asthma, a group deliberately weighted toward the populations registration trials rarely reach — smokers, adolescents, Black patients, people whose asthma overlaps with COPD, patients with other lung conditions. And the results were exactly what a commercial launch wants. Tezspire cut asthma attacks by 70% across those subgroups, and the safety profile stayed consistent with earlier trials, with no new safety signals identified. For a biologic whose economics rest on keeping patients on therapy and widening the population it treats, that is confirmation, not a surprise.

Now the size of it. Tezspire sold $486 million in the second quarter, up 42% from a year earlier, one of six named growth drivers that collectively grew 26% and produced roughly 70% of quarterly product sales. That is real compounding. It is also roughly 5% of the $10.1 billion in revenue Amgen just posted. A readout that validates Tezspire extends the runway of one growth engine; it does not, by itself, change what the market pays for the whole company.

What the market pays is the part the headline skips. Amgen sits at $440, up 34.5% year to date, within a couple of percent of its 52-week high, with a 14-day RSI near 71 — the overbought neighborhood where the easiest money in a trade is usually already made. And it arrives after a 53% advance over the past rolling year.

That tension is worth running through the factor stack, because the business itself is genuinely good. Growth: revenue up 10% in the second quarter, against a big-pharma peer group where flat is common. Profitability: gross margin around 68%, operating margin near 28%, return on invested capital about 15% — top of the comparator set. Revisions, which matter most: non-GAAP EPS of $6.29 beat the roughly $5.60 consensus, revenue of $10.1 billion cleared estimates by several hundred million, and management raised its full-year guidance to $38.2–$39.4 billion of revenue and $22.30–$23.50 of non-GAAP EPS. In fancier language, this is an improving report card, the direction my process values as much as the level.

Valuation is where the story thins out. Amgen trades at roughly 17.5 times EV/EBITDA, mid-pack against big pharma — well below Merck and Pfizer in the low 30s, above Bristol Myers near 9, comparable to Johnson & Johnson at 20. Trailing P/E is about 27. And there is no single honest P/E to quote, because the answer depends on which earnings you use. Reported GAAP second-quarter earnings were $4.37 a share; non-GAAP was $6.29, a gap driven largely by amortization of intangibles from Amgen's $27.8 billion Horizon acquisition, its largest ever. On the guided numbers, that same $440 price is about 19 times non-GAAP 2026 earnings and roughly 27 times guided GAAP earnings. "Amgen is cheap" is a sentence that only works once you pick a basis — and the basis that makes it cheap excludes the biggest charge on the income statement.

The weak factor, unsurprisingly, is the balance sheet. Net debt runs about $43 billion, debt-to-equity near 490%, the footprint of the Horizon deal. Free cash flow of roughly $10 billion a year covers the dividend — about 2.2% yield with 14 consecutive years of increases — but the leverage is why the safety factor scores below most peers, and why the rest of the stack has to work harder.

So where does this leave a decision? The aggregate data cross-check lands in the same place as the factor read: AInvest's signal currently labels Amgen a Hold. That label is not a verdict on the company — it is a statement that the growth and the risk are both already visible at this price. In process terms, Hold is not Sell. This is a proven winner with an improving report card, and the discipline says let it run rather than cut it. What Hold does say is that this is not the entry a patient investor should be chasing at RSI 71.

The wildcard that turns all of this into a conditional is MariTide, the obesity drug Amgen is running through nine Phase 3 trials as a monthly, or less frequent, alternative to the weekly diabetes shots — and it is now the company's sole obesity candidate after it dropped a Phase 1 sibling. A meaningful share of the 34.5% year-to-date move is the market paying for a seat in the obesity market. That is optionality, not a factor grade: MariTide shows up in none of the trailing numbers above. If Phase 3 disappoints, the multiple reverts toward a normal big-pharma valuation, and the leverage means there is less cushion than a cleaner balance sheet would provide.

The consistent Tezspire data earns its headline. It does not earn a new buy at this price, in this setup. For a holder, the improved report card supports owning through, with MariTide Phase 3 as the specific event that rewrites the case either way. For someone without a position, this reads as a quality-growth-with-yield sleeve to accumulate into weakness rather than chase: a pullback toward the 50-day average near $384 restores the kind of entry the factor stack can justify at a mid-pack multiple. When the price has run ahead of the persistence the data can prove, the process answer is not more conviction. It is a better price.